HFCAS OpenIR

浏览/检索结果: 共1条,第1-1条 帮助

限定条件    
已选(0)清除 条数/页:   排序方式:
Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39
作者:  Song, Yuqin;  Gao, Quanli;  Zhang, Huilai;  Fan, Lei;  Zhou, Jianfeng;  Zou, Dehui;  Li, Wei;  Yang, Haiyan;  Liu, Ting;  Wang, Quanshun;  Lv, Fangfang;  Guo, Haiyi;  Yang, Liudi;  Huang, Jane;  Novotny, William F.;  Wang, Yidi;  Zhu, Jun
收藏  |  浏览/下载:55/0  |  提交时间:2022/01/10